Cargando…

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers

Rebouissou et al. recently provided preclinical evidence that a subset of patients with muscle-invasive bladder cancer might benefit from anti-epidermal growth factor receptor (EGFR) therapy and reported diagnostic tools for identifying these patients in the clinical setting. This work also identifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lebret, Thierry, Neuzillet, Yann, Houede, Nadine, Rebouissou, Sandra, Bernard-Pierrot, Isabelle, De Reynies, Aurélien, Benhamou, Simone, Allory, Yves, Radvanyi, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905367/ https://www.ncbi.nlm.nih.gov/pubmed/27308521 http://dx.doi.org/10.1080/23723556.2014.999507

Ejemplares similares

A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression
por: Vallot, Céline, et al.
Publicado: (2011)

A prospective multicenter study on bladder cancer: the COBLAnCE cohort
por: Benhamou, Simone, et al.
Publicado: (2016)

IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer
por: Neuzillet, Yann, et al.
Publicado: (2017)

An essential role for decorin in bladder cancer invasiveness
por: El Behi, Mohamed, et al.
Publicado: (2013)

Deregulation of Rab and Rab Effector Genes in Bladder Cancer
por: Ho, Joel R., et al.
Publicado: (2012)

Recurrent activating mutations of PPARγ associated with luminal bladder tumors
por: Rochel, Natacha, et al.
Publicado: (2019)

Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks
por: Neyret-Kahn, Hélène, et al.
Publicado: (2023)

New insights on the role of CD8(+)CD57(+) T-cells in cancer
por: Wu, Richard C., et al.
Publicado: (2012)

A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer
por: Neuzillet, Yann, et al.
Publicado: (2012)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non–muscle-invasive bladder cancer and with low and intermediate EORTC-risk score
por: Simon, Marie, et al.
Publicado: (2019)

Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

Author Correction: Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer
por: Rouanne, Mathieu, et al.
Publicado: (2021)

AEG-1–AKT2: A novel complex controlling the aggressiveness of glioblastoma
por: Emdad, Luni, et al.
Publicado: (2015)

A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE Cohort
por: Karimi, Maryam, et al.
Publicado: (2023)

Oncogenic regulatory circuits driven by 19q13 rs11672691 underlies prostate cancer aggressiveness
por: Xia, Ji-Han, et al.
Publicado: (2018)

Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer
por: Nassif, Elise F., et al.
Publicado: (2021)

Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination
por: Jinesh G., Goodwin, et al.
Publicado: (2012)

RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment
por: Said, Neveen, et al.
Publicado: (2012)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies
por: Lang, Hervé, et al.
Publicado: (2022)

Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis
por: Labidi-Galy, Sana Intidhar, et al.
Publicado: (2012)

Blocking IL-10 enhances bacillus Calmette-Guérin induced T helper Type 1 immune responses and anti-bladder cancer immunity
por: Luo, Yi
Publicado: (2012)

Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?
por: Godet, Yann, et al.
Publicado: (2012)

BORA-dependent PLK1 regulation: A new weapon for cancer therapy?
por: Cirillo, Luca, et al.
Publicado: (2016)

TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer
por: Dufour, Florent, et al.
Publicado: (2019)

Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors
por: Lerret, Nadine M., et al.
Publicado: (2013)

Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination
por: Dosset, Magalie, et al.
Publicado: (2013)

Regulation of cancer stem-like cell differentiation by Smac mimetics
por: Fulda, Simone
Publicado: (2014)

Cell-penetrating peptides—the Swiss Army knife of cancer vaccines
por: Walker, Paul R., et al.
Publicado: (2015)

Tumor microenvironment in NSCLC suppresses NK cells function
por: Cremer, Isabelle, et al.
Publicado: (2012)

Flicking the molecular switch underlying MLKL-mediated necroptosis
por: Hildebrand, Joanne M, et al.
Publicado: (2015)

Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells
por: Larmonier, Nicolas, et al.
Publicado: (2012)

Immunotherapy of HPV-associated head and neck cancer: Critical parameters
por: Nizard, Mevyn, et al.
Publicado: (2013)

Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment
por: Ménétrier-Caux, Christine, et al.
Publicado: (2012)

DEC-205 is a cell surface receptor for CpG oligonucleotides
por: Caminschi, Irina, et al.
Publicado: (2013)

ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells
por: Faget, Julien, et al.
Publicado: (2013)

Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
por: Michaud, Mickaël, et al.
Publicado: (2012)

No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study
por: Ascierto, Paolo A., et al.
Publicado: (2020)

Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients
por: Sisirak, Vanja, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mv1vjahbs78ncbinrsebvbfshu